Drug Trial Radar · NCT05646758
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
140
Planned (sponsor's estimate)
Start
Mar 17, 2023
Primary completion
Oct 2024
Study completion Oct 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen) double-specific antibody,and the isoform is IgG1 (Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.TQB2934 for injection is planned for the treatment of patients with multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
TQB2934 injectionDrug
TQB2934 is an anti-CD3×BCMA double-specific antibody,which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: Up to 18 months
- Maximum Tolerated Dose (MTD)Time frame: Up to 18 months
- Incidence and severity of serious adverse events (AEs)Time frame: Up to 18 months
- Incidence and severity of adverse events (AEs)Time frame: Up to 18 months
- Incidence and severity abnormal laboratory test valueTime frame: Up to 18 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-Sen University Cancer Canter
Guangzhou, Guangdong, China · Recruiting
The Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Shandong First Medical University Affiliated Tumor Hospital
Jinan, Shandong, China · Recruiting
Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.